Chronic Cerebrospinal Venous Insufficiency and Multiple Sclerosis

(65 characters)

Omar Khan, MD¹; Massimo Filippi, MD²; Mark S. Freedman, MD, FRCPC³; Frederik Barkhof, MD, PhD⁴; Paula Dore-Duffy, PhD¹; Hans Lassman, MD⁵; Bruce Trapp, PhD⁶; Amit Bar-Or, MD, FRCPC⁷; Imad Zak, MD⁸; Marilyn J. Siegel, MD, FACR⁹; Robert Lisak, MD, FRCP¹

¹Multiple Sclerosis Center, Department of Neurology, Wayne State University School of Medicine, Detroit; ²Neuroimaging Research Unit, Scientific Institute and University Hospital San Raffaele, Milan; ³Multiple Sclerosis Research Unit, The Ottawa Hospital General Campus, University of Ottawa, Ottawa; ⁴Department of Radiology and Amsterdam MS Center; VU University Medical Center, Amsterdam; ⁵Centre for Brain Research, Medical University of Vienna, Vienna; ⁶Department of Neurosciences; Lerner Research Institute, Cleveland Clinic, Cleveland; ⁷Montreal Neurological Institute, McGill University, Montreal; ⁸Department of Radiology; Wayne State University School of Medicine, Detroit; ⁹Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis

Running Head: Venous insufficiency in multiple sclerosis (42 characters)

Abstract word count: 191, Manuscript word count: 2482; Figures: 0; Tables: 0
Corresponding Author:
Omar Khan, MD,
Multiple Sclerosis Center & Image Analysis Laboratory,
Department of Neurology, Wayne State University School of Medicine
4201 St Antoine, 8A-UHC,
Detroit, Michigan 48323
Tel: (313) 745-4280;
Fax: (313) 966-9271
Email: okhan@med.wayne.edu
Abstract

A chronic state of impaired venous drainage from the central nervous system, termed as chronic cerebrospinal venous insufficiency (CCSVI), is claimed to be a pathologic phenomenon exclusively seen in multiple sclerosis (MS). This has invigorated the causal debate of MS and generated immense interest in the patient and scientific communities. A potential shift in the treatment paradigm of MS involving endovascular balloon angioplasty or venous stent placement has been proposed as well as conducted in small patient series. In some cases, it may have resulted in serious injury. In this “Point of View”, we discuss the recent investigations that led to the description of CCSVI as well as the conceptual and technical shortcomings that challenge the potential relationship of this phenomenon to MS. The need for conducting carefully designed and rigorously controlled studies to investigate CCVSI has been recognized by the scientific bodies engaged in MS research. Several scientific endeavors examining the presence of CCSVI in MS are being undertaken. At present, invasive and potentially dangerous endovascular procedures as a therapy for patients with MS should be discouraged until such studies have been completed, analyzed, and debated in the scientific arena.
Recently, the topic of chronic cerebrospinal venous insufficiency (CCSVI) and its potential relationship to multiple sclerosis (MS) has generated tremendous interest in the news media, spilling over to the patient and scientific communities. Described as a state of chronic impaired venous drainage from the central nervous system (CNS), the emergence of CCSVI with respect to MS is based on the work done by Zamboni and colleagues (1). This was followed by a small open-label study conducted to study the effect of endovascular angioplasty in MS patients with CCSVI (2). Prompted by these series of events, this “Point of View” will review available information on CCSVI, its potential relationship to MS pathology, and what further research needs to be undertaken while keeping patient safety foremost.

Transcranial color-coded Doppler sonography (TCCS) is a technique that superimposes a color-coded image of blood flow of intracranial vessels on the gray scale image to evaluate intracranial veins. By combining TCCS and extracranial color-Doppler sonography (ECD), Zamboni and colleagues studied 109 MS patients and 177 matched controls (3). Based on venous flow parameters established in their laboratory, they found 288 normal and 257 anomalous TCCS-ECD parameters in MS patients. In contrast, 861 normal and 24 anomalous parameters were seen in control subjects. The authors focused in particular on five anomalous parameters of cerebral venous drainage: (i) reflux in the internal jugular (IJV) and vertebral veins (VV), (ii) reflux in the deep cerebral veins (DCV), (iii) high-resolution B-mode evidence of IJV stenosis, (iv) flow not
Doppler-detectable in the IJV and/or the VV, and (v) reverted postural control of the main cerebral venous outflow pathways. They claimed that these parameters were not seen in normal subjects, although others have reported internal jugular vein valve insufficiency in 29 to 38% of healthy volunteers under pressure-controlled maneuvers (4,5). In the study by Zamboni and colleagues (1), the presence of at least two of these anomalous parameters in a single subject was defined as abnormal. They reported that only MS patients and not controls met the criteria for abnormal extracranial cerebral venous outflow. This observation perfectly overlapped with the diagnosis of MS, with a reported 100% sensitivity, 100% specificity, 100% positive predictive value, and 100% negative predictive value, highly unusual findings in clinical research. With such high level of diagnostic accuracy, these findings could reflect spectrum bias, which occurs when a diagnostic test is assessed under sampling conditions that are not unlikely to be clinically representative (6). Moreover, these findings are not easy to interpret because it is difficult to determine flow in the deep cerebral veins using ultrasound since the angle of insonation is greater than 60 degrees. There is also the potential of interference arising from the pulsation signal of the posterior communicating artery located adjacent to the draining jugular sinuses.

In a separate study, 65 MS patients and 235 controls underwent TCCS-ECD (1). While the technician and the interpreting physician were blinded to the diagnosis, it is not clear if the performing sonographer was blinded to the diagnosis. The authors claim report that they were able to separate 100% of MS patients from controls, also a difficult result to achieve. All 65 MS patients, as part of a non-
blinded sub-study, underwent selective catheterization of the IJV and azygous veins (AV) (1). They found that IJV and AV were stenosed in 91% and 86% of the patients, respectively. More recently, percutaneous transluminal angioplasty (PTA) was performed in these 65 MS patients, who were then followed for up to 18 months (2). During this period, it was determined that some of the clinical outcomes were improved, mostly in the relapsing-remitting MS cohort (35/65).

However, the small sample size, lack of controls, unblinded neurologic evaluations, significant re-stenoses of 47% IJV, and inconsistent MRI protocols limit the interpretation of their data. Due to high re-stenosis rate, they suggested that a “logical alternative would be stent insertion” (2). Furthermore, all patients remained on their disease modifying therapies, making any interpretation of “efficacy” even more tenuous. In a separate publication, the same investigators imply that CCSVI causes venous reflux leading to iron build up in the brain, which may be a primary event in the MS disease pathology, triggering subsequent inflammatory injury to the CNS (7). The potential role of increased iron deposition in the brain and iron-mediated injury to the CNS is not exclusive to MS and is well-documented in many neurological disorders, particularly neurodegenerative diseases this phenomenon is not exclusive to MS (8,9). Yet, CCSVI was never observed in the “other neurologic disease” controls studied by Zamboni and colleagues that included Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (1).

As a result of the great deal of media attention that has been given to CCSVI, the
causal debate of MS has been invigorated by the work of Zamboni and colleagues, who euphemistically refer to the endovascular treatment of the “blocked” veins in MS patients as the “Liberation” treatment. Consequently, thousands of patients have expressed an interest in volunteering for studies to examine if they have stenoses or blockages of the IJV and AV. Anecdotal reports suggest that some sites in the U.S. and Europe have undertaken endovascular procedures for MS patients including venous “stenting”.

Despite the intriguing results and claims the results reported by Zamboni and colleagues, their data should be considered preliminary at best. There is no doubt that their work though preliminary, have raised many questions regarding the cause of MS, and how it may be treated based on the theory of CCSVI. This necessitates carefully conducted and “dispassionate” research exploring the possibility that CCSVI might indeed contribute to the pathogenesis of MS. Many questions must also be addressed regarding CCSVI and MS with. The intracranial venous return has not been routinely investigated by TCCS in the normal population. The work done by Zamboni and colleagues (1), though innovative, is limited by the lack of discussion of TCCS technique and the absence of a reference standard, such as MRI, for intracranial vascular evaluation. The vessels evaluated by Zamboni and colleagues included the extracerebral veins (VV and IJV) and at least one of the deep cerebral veins (basal vein of Rosenthal, great vein of Galen, or internal cerebral veins). This approach introduces variation into the results, since ideally, all three deep
cerebral veins should have been examined. In a prior study by the same investigators, they noted that the main parameters of TCCS investigation of the intracranial veins are the flow parameters, such as flow direction, flow velocity, and resistive index (10). However, these parameters do not appear to have been evaluated in their CCSVI study in MS patients (1), which also lacked figures of TCCS images to document the results the authors described. Lack of MRI for examining the intracranial vessels and lesion distribution did not allow the evaluation of the plaques’ topography with the refluxing veins. Collectively, these limitations necessitate a more cautious interpretation of their findings. It also makes the robustness of this approach to investigate intracranial venous return, unclear.

Several well-known features of MS including the autoimmune nature of the disease involving complex T and B-cell mediated responses (11), challenge CCSVI as the etiology of MS or even contributing to the disease pathophysiology. Is the presence of cranial venous outflow stenosis and formation of substitute venous circulation “circles”, largely a phenomenon observed in women since nearly two-thirds of the MS patients are women? (12). Interestingly, most other systemic autoimmune diseases also show greater prevalence in women than men, although, stagnant venous outflow may not be germane to the known pathology of those diseases such as lupus and rheumatoid arthritis (13). Since the peak age of incidence of MS is between 25 and 35 years (14), it is unclear why it would take two to three decades for a
stagnant venous drainage to lead to the development of MS. At the same time, being a “vascular” phenomenon, it would be logical to expect a chronically stagnant venous flow from the CNS, only to get worse and more prevalent over time. Yet the incidence of MS becomes rare at age 50 years and older (14).

Similarly, MS is rare in the tropics and subtropics (16), yet there is no published report of chronic venous flow disorders based on similar geographic incidence and prevalence.

Several genetic susceptibility factors for MS have been identified including MHC and non-MHC loci (15). Also noteworthy is that first-degree relatives of MS patients are 20 to 50 times more likely to develop MS than the general population (18). The presence of HLA-DR2 increases the risk of developing MS and other autoimmune disorders, primarily through association with T-cell mediated responses (16,17). However, there is no data to suggest how these allelic expressions may alter cerebrospinal venous flow or what makes first-degree relatives of MS patients more susceptible to venous blockages if that is hypothesized to be the underlying pathology leading to the development of MS. It is also well-known that genetic predisposition alone can not explain the significant differences in risk among people of common ancestry who migrate to areas of high or low MS prevalence (18). The geographic distribution of MS and the resultant change in risk among migrant population provide strong evidence in support of “environmental” risk factors for developing MS (19,20). Data related to sun light exposure in association with low vitamin D level and immune response...
to EBV infection are associated with a higher risk of developing MS in the pediatric clinically isolated syndrome (CIS) population, challenging the hypothesis that MS is more likely to be a consequence of venous stasis (21,22).

Several lines of evidence suggest that MS pathogenesis includes an environmental trigger that first primes the immune system and then initiates an immune response to unknown CNS antigens including myelin antigens (23,24). However, currently, there is no precedence for reduced venous drainage and induction of an organ-specific immune response. Moreover, the presence of CSF oligoclonal bands indicative of intrathecal humoral response, is not exclusive to MS and may be seen in several other CNS disorders in which the pathology is unlikely to be affected by abnormalities of the cerebrospinal venous circulation (28). Other histopathologic studies have shown early loss of oligodendrocytes in active MS lesions and the absence of lymphocytes in the perivascular spaces as a key feature of MS pathology (25). The contribution of CCSVI to this observation is also unclear.

The pathology of MS, characterized by the hallmark of inflammatory demyelination, is different from that seen in conditions of Venous occlusion secondary to flow disturbances The latter is characterized by hemorrhagic and ischemic infarctions, and edema associated with increased intracranial pressure (26). These features are not typically seen in the brain or spinal cord of MS patients. Furthermore, the widespread primary demyelination, characteristic for both white and grey matter lesions in MS patients (27) is not present in
conditions of acute or chronic venous brain disease. However, more subtle chronic alterations of venous blood flow could theoretically augment tissue injury in MS. Chronic perivenous inflammation in the brain may release inflammatory mediators into the venous lumen and consequently, alter venous endothelium.

vessel walls in the drainage pathways. In such a case, A disturbance of venous outflow may increase pressure within the venous drainage pathways. This is likely to facilitate may which by itself may make it easier for the exit of inflammatory cells to leave from the venous circulation in the small veins and venules, to gain entry into the CNS, and amplify perivenous inflammation.

However, it was recently shown that in the late stages of MS, inflammation may die out and decline to levels seen in age-matched controls (28). This would not be the case, if impaired venous drainage was the primary pathology in MS cause of the problem-since it would be expected to imagine such a problem actually increase with time and age. High-field susceptibility-weighted imaging at 3 Tesla has shown reduced visibility of venous vasculature in the periventricular white matter in MS patients compared to controls suggestive of a diffuse hypometabolic process (32). However, in CCSVI, one would anticipate the venous vasculature to be more prominent due to impaired venous drainage and higher venous luminal pressure. In CCSVI, presumably, the retinal and ophthalmic venous systems that ultimately drain into the internal jugular veins, are likely to have impaired venous drainage due to CCSVI. While Equally intriguing is extrapolating the argument of impaired venous drainage associated with optic neuritis is a common clinical occurrence in MS, venous stasis
retinopathy is not. The latter represents the earliest stages of chronic ocular ischemia, characterized by a variety of retinal hemorrhages (29). In contrast, however, while retinal nerve fiber layer (RNFL) atrophy is a well recognized feature of MS common occurrence in MS (30), venous stasis retinopathy that usually is not a feature of MS. It would not be logical to disassociate one form of retinal injury from the other, if all are a result of impaired ocular venous drainage.

Also suggested by Zamboni et al (1), chronic inefficient venous drainage from the azygous vein accounts for the clinical manifestations of spinal cord involvement in MS i.e. recurrent episodes of transverse myelitis and progressive myelopathy. Histopathologic studies show both axonal loss and demyelination in the spinal cord in MS (31,32) but not the typical features expected from raised intra-luminal venous pressure (26). Furthermore, the venous drainage of the spinal cord is complex and comprised of at least four distinct intercommunicating systems: (i) intrinsic small capillary veins, (ii) extrinsic veins (including pial, collector, and radicular veins), (iii) internal vertebral venous plexus, and (iv) external vertebral venous plexus (33). These venous systems communicate with occipital, basilar, vertebral, intercostal, lumbar and lateral sacral veins (34). The intramedullary veins drain the spinal cord parenchyma and also participate in extensive transmedullary anastomoses (35). The lumbar veins also communicate with the inferior vena cava. Cadaver studies have shown that venous reflux through the radicular veins appears to be a physiologic phenomenon with a regulatory mechanism protecting the spinal cord from high venous pressure (34). Therefore,
Given the complex venous drainage system of the spinal cord inherent with extensive protective communicating systems, makes chronic venous insufficiency of the azygous vein unlikely to be responsible for the clinical and histopathologic features of spinal cord involvement in MS.

Increased cerebral venous pressure occurs in central venous thrombosis, idiopathic intracranial hypertension, pulmonary hypertension, and chronic obstructive pulmonary disease (36-38), yet, none of these disorders are associated with MS or pose a risk of developing MS. Interestingly, transient global amnesia is well known to occur in association with jugular venous insufficiency (39,40), but is not a feature of MS. Radical neck dissection is a standard surgical procedure in the management of head and neck cancer, which besides extensive malignant and non-malignant tissue removal, removes all jugular veins and associated lymph nodes en bloc (41). Multiple sclerosis or related inflammatory demyelinating disorders of the CNS have never been reported as a complication of radical neck dissection in over a century since the original description of this procedure in 1906 (42). Brain MRI scan obtained several weeks after bilateral internal and external jugular venous ligation, did not reveal any lesions or parenchymal abnormalities (43), and brain MRI scans in the long-term follow up of patients who have previously undergone radical neck dissection have not shown any pathology suggestive of MS (personal observations, IZ). The cerebrospinal venous architecture is a highly complex and evolved system of venous blood flow with numerous variations, collaterals, and
even the possibility of a watershed zone separating the periventricular venous drainage from the deep white matter venous flow (44, 45). This further raises questions regarding the results of the study by Zamboni et al. (1), claiming the ability to completely (100%) distinguish MS patients from controls with TCCS-ECD criteria established in their laboratory.

These and many other arguments that challenge the theory of CCSVI proposed by Zamboni and colleagues, should lead to a constructive scientific debate. and research to reproduce their preliminary findings. Association, if proven, should not be construed as causality. There is also the possibility that the development of venous flow abnormalities may be secondary to other diseases processes in MS. This could be partly addressed by examining patients for the presence of CCSVI in the earliest stages of the disease i.e. CIS or children with MS. The role of the autonomic nervous system and the technical variations in the application of TCD studies, as it may apply to MS have to be carefully considered (46-48).

Future TCD studies should involve multiple sites to overcome the well-known limitations of single site studies, especially in the application and acceptance of abnormal parameters of cerebrospinal venous flow since there is no published consensus on standardized criteria for normal venous return using ECS-TCCD. Studies employing MR venography (MRV) to examine “venous” stenosis” in MS will have to examine both “caliber” and “hemodynamic” flow abnormalities, as well as determine the significance of these potential findings. In contrast to studies examining carotid artery stenosis and its clinical significance (49,50),
there is no such data for IJV or AV. Meticulously conducted MRV studies from multiple centers, may be needed to provide insight into CCSVI and its potential relationship with MS. The inclusion of carefully selected control population in these studies can not be overemphasized. Furthermore, attempts should be made to Correlation of CCSVI with the well-established clinical, immunologic, histopathologic, and imaging features of MS needs to be investigated.

It would be critical not to compromise patient safety to ensure that during the conduct of these research endeavors, patient safety never be compromised.

Anecdotal reports have indicated that endovascular procedures including placement of stents in the internal jugular vein have been carried out in MS patients as a “clinical treatment procedure”, and in some cases have led to serious injury. Potentially fatal outcomes including migration of the venous stent into the heart and perforation of the ascending aorta are uncommon but known complications of venous stent insertions (51,52). Therefore, Any invasive endovascular procedures including angioplasty and venous stent placement should be discouraged until there is conclusive evidence to justify their indication in MS. Attempts should be made to study the plausibility of CCSVI in MS and to correlate it with the well-known clinical features of the disease along with seminal observations from the vast immunologic, histopathologic, and imaging studies conducted over the past several decades.
Acknowledgement

The authors wish to thank Drs Kumar Rajamani, John Kamholz and Scott Millis
(Wayne State University); Mike Wattjes and Chris Polman (VU Amsterdam); and
Sami Harik (University of Arkansas) for their helpful comments and critical review
of the manuscript.

Financial Interests

Dr Khan has received research support from the National MS Society (NMSS),
the National Institutes of Health (NIH), Teva Neuroscience, Genzyme
Corporation, Biogen Idec, Novartis Pharmaceuticals, and Acorda Therapeutics;
consultancy and speaking honoraria from Teva Neuroscience, Biogen Idec,
Novartis Pharmaceuticals, and Bayer Healthcare. Dr Lisak has received research
support from the NMSS, NIH, Teva Neuroscience, and Questcor; consultancy
and speaking honoraria from Teva Neuroscience and Bayer Healthcare. Dr
Barkhof has received research support from the Dutch MS Research Foundation
and Merck-Serono; consultancy and speaking honoraria from EMD Merck-
Serono, Bayer-Schering Pharma, Biogen-Idec, UBC, Sanofi-Aventis, Novo-
Nordisk. Dr Trapp has received research support from the NIH, NMSS, Canadian
MS Society, Ohio Third Frontier, Vertex, and EMD Merck-Serono; consultancy
and speaking honoraria from Teva Neuroscience, Biogen Idec and Pfizer. Dr.
Bar-Or has received research support from the MS Society of Canada (MSSC)
and the MSSC Research Foundation, The Canadian Institutes of Health
Research, the FRSQ, Bayhill Therapeutics, Biogen Idec, Bio MS, Genentech,
and Teva Neuroscience; consultancy and speaking honoraria from Biogen Idec, Eli Lilly, Genentech, MerckSerono, Novartis, Roche and Teva Neuroscience.

Dr Dore-Duffy has received research support from the NMSS and the NIH. Dr Filippi has received research support from Bayer-Schering Pharma, Biogen-Dompé AG, Genmab A/S, Merck Serono, Teva Pharmaceutical Industries Ltd., Fondazione Italiana Sclerosi Multipla (FISM), and Fondazione Mariani; consultancy and speaking honoraria from Bayer Schering Pharma, Biogen-Dompé AG, Genmab A/S, Merck Serono, Teva Pharmaceutical Industries Ltd. Dr Freedman has received research support from the Canadian MS Society, EMD Merck-Serono, Genzyme, and Bayer Schering Pharma; consultancy and speaking honoraria from Teva Neuroscience, Bayer Healthcare, and EMD Merck-Serono. Drs Siegel, Lassmann, and Zak have nothing to disclose.
References:


40. Lewis SL. Aetiology of transient global amnesia. Lancet 1998;352:397-


42. Crile, G. Excision of cancer of head and neck. JAMA 1906;47:1780-1786


49. North American Symptomatic Carotid Endarterectomy Trial Collaborators

